CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

022454Orig1s000

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

31 AUGUST 2009

NDA: 22-454

Drug Product Name
Proprietary: DaTSCAN
Non-proprietary: loflupane I 123 Injection

Review Number: 1

Dates of Submission(s) Covered by this Review

Letter	Stamp	Review Request	Assigned to Reviewer
6 March 2009	9 March 2009	N/A	19 March 2009
19 June 2009	23 June 2009	N/A	N/A
11 August 2009	12 August 2009	N/A	N/A
21 August 2009	24 August 2009	N/A	N/A

Submission History (for amendments only): N/A

Applicant/Sponsor
Name: GE Healthcare
Address: 101 Carnegie Center, Princeton, NJ 08540-6231
Representative: Allison Mueller
Telephone: 609-514-6843

Name of Reviewer: Bryan S. Riley, Ph.D.

Conclusion: Recommended for Approval

Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: Original NDA [505(b)(1)]

2. SUBMISSION PROVIDES FOR: A sterile parenteral drug product.

3. MANUFACTURING SITE: GE Healthcare
3350 North Ridge Avenue
Arlington Heights, IL 60004

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: Sterile solution for intravenous administration 2.5 mL fill in a 10 mL unit dose vial. 2 mCi/mL.

5. METHOD(S) OF STERILIZATION: (b) (4)

6. PHARMACOLOGICAL CATEGORY: Imaging Agent

B. SUPPORTING/RELATED DOCUMENTS: BB-MF (b) (4)

C. REMARKS: This was an eCTD submission. An IQA was performed by the ONDQA PAL and placed into DFS on 30 March 2009. A product quality microbiology information request was sent to the applicant after the filing review. The equipment autoclave cycle parameters and process validation summary were requested. A biologics master file (BB-MF (b) (4) was referenced for the (b) (4) However, the sterilization validation was not provided in the Master File. Two additional information requests were then sent to the applicant regarding the sterilization validation for (b) (4). Three amendments were submitted in response to the information requests.

filename: N022454R1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability – Recommended for approval from the standpoint of product quality microbiology.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable – N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – The drug product is (b) (4)

B. Brief Description of Microbiology Deficiencies – N/A

C. Assessment of Risk Due to Microbiology Deficiencies – N/A

III. Administrative

A. Reviewer's Signature _____

Bryan S. Riley, Ph.D.
Senior Review Microbiologist OPS/NDMS

B. Endorsement Block _____

Stephen Langille, Ph.D.
Senior Review Microbiologist OPS/NDMS

C. CC Block

N/A

6 Page(s) has been Withheld in Full as B4 (CCI/TS) immediately following this page

Linked Applications	Submission Type/Number	Sponsor Name	Drug Name / Subject
NDA 22454	ORIG 1	GE HEALTHCARE INC	DA TSCAN

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRYAN S RILEY
08/31/2009

STEPHEN E LANGILLE
08/31/2009

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 22-454 **Applicant:** GE Healthcare **Letter Date:** 6 March 2009

Drug Name: DaTSCAN **NDA Type:** 505(b)(1) **Stamp Date:** 9 March 2009

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		eCTD submission
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?	X		
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		N	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?	X		
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	X		
7	Has the applicant submitted the results of analytical method verification studies?	X		
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?	X		
9	Is this NDA fileable? If not, then describe why.	X		

Additional Comments: The applicant has not supplied the details of the autoclave processes used to sterilize the filling equipment or the validation of those autoclave processes. An information request will be sent to the applicant to request the missing information.

21 April 2009

Bryan S. Riley, Ph.D. Date
Senior Review Microbiologist

James L. McVey Date

OPS/NDMS Team Leader

Appears this way on original

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Bryan Riley
5/1/2009 07:33:10 AM
MICROBIOLOGIST

James McVey
5/1/2009 09:58:52 AM
MICROBIOLOGIST
I concur.